Early Treatment of Migraine With Rizatriptan: A Placebo‐Controlled Study
Authors:
- Jayasree KailasamJKJayasree Kailasam
- Lori MeadorsLMLori Meadors
- 18 June 2004
- journal article
- clinical trial
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 44 (7) , 669-673
Abstract
Objective.—To evaluate the efficacy of rizatriptan when administered early during a migraine attack.Background.—Several studies indicate that triptans are more efficacious when administered early during a migraine attack, when the pain is still mild.Methods.—One hundred and twelve rizatriptan‐naïve patients aged 20 to 64 years with a history of migraine with or without aura that progressively worsened when left untreated were instructed to treat a total of three migraine attacks with either rizatriptan 10 mg or placebo as early as possible during each attack. Seventy‐four patients (68 women and 6 men) were assigned to use the active drug and 38 (35 women and 3 men) to placebo. The primary efficacy endpoint was pain‐free response at 2 hours after administration of the study drug. Secondary efficacy measures were pain‐free response at 1 hour and sustained pain‐free response lasting between 2 and 24 hours.Results.—A total of 216 attacks were treated in the rizatriptan group and 109 in the placebo group. Pain‐free response at 2 hours after early treatment was noted in 151 (70%) of attacks in the rizatriptan group and in 24 (22%) in the placebo group (P < .01). Pain‐free response at 1 hour occurred in 97 (45%) and 9 (8%) attacks, respectively (P < .01). When the attacks were categorized by headache severity at the time of treatment, the pain‐free response at 2 hours was higher for mild attacks than for moderate or severe attacks (P < .01). Sustained pain‐free response after treatment was significantly higher for attacks treated with rizatriptan (60%) than for those treated with placebo (17%) (P < .001). Adverse events were observed in 62 patients in the rizatriptan group and 15 in the placebo group. Only 1 patient taking rizatriptan discontinued the study because of adverse events, and no serious adverse events were reported.Conclusions.—Rizatriptan is significantly more likely than placebo to produce a pain‐free response within 2 hours when the drug is administered early in the migraine attack, when pain is mild rather than moderate or severe.Keywords
This publication has 17 references indexed in Scilit:
- Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: A Randomized, Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2002
- Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trialsThe Lancet, 2001
- Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum StudyHeadache: The Journal of Head and Face Pain, 2000
- Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum StudyHeadache: The Journal of Head and Face Pain, 2000
- Comparison of Rizatriptan 10 Mg vs. Zolmitriptan 2.5 Mg in the Acute Treatment of MigraineCephalalgia, 2000
- Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 1998
- Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in MigraineHeadache: The Journal of Head and Face Pain, 1998
- The Long‐term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 31X90) in the Acute Treatment of Migraine. An International StudyHeadache: The Journal of Head and Face Pain, 1998
- Rizatriptan vs Sumatriptan in the Acute Treatment of MigraineArchives of Neurology, 1996
- Absorption of Effervescent Aspirin during MigraineBMJ, 1974